For how we live.
In the Nordic SWEDEGRAFT trial, the no-touch vein-harvesting technique left the rate of death, heart attack, or repeat procedures at 19.8% versus 20.4% through seven years — a difference indistinguishable from chance.
Bristol Myers Squibb's mavacamten gained an FDA efficacy supplement on 30 September. In the pivotal EXPLORER-HCM trial, 37% on the drug met the primary endpoint versus 17% on placebo.
TRICORDER put an AI-enabled stethoscope into UK primary care. Over a year it did not increase heart-failure diagnoses population-wide, even though the device, when actually used, flagged more disease.
A 2,234-patient UK trial gave people with unexplained syncope a 14-day ECG monitor or usual care. A year on, fainting episodes were no fewer — a caution against confusing better detection with better outcomes.
In 264 patients in China, the device maker's trial reported clinical worsening in 25.7% versus 51.5% on medical therapy alone (HR 0.49) — but no sham procedure blinded patients.
The first double-blind sham-controlled trial of pulmonary vein isolation found quality of life improved in both arms. Most of the benefit patients feel appears not to come from the ablation.
THESUS-HF II enrolled 1,578 patients across 50 hospitals in 17 countries. Guideline drugs were prescribed at discharge in most patients, and target doses were reached in fewer than half.
Two 2026 studies found people with no ultrasound background produced diagnostic-quality echocardiograms after about a day of AI-guided training. Quality varied sharply by view, finding, and who was holding the probe.
A secondary analysis of the VITAL-AF trial reports a screening benefit only in the top risk decile — with a confidence interval whose lower bound sits at 0.01.
Among 1.2 million participants in Paris endurance races over ten years, 17 suffered sudden cardiac arrest. Nearly all of them lived, and researchers still can't explain almost half the cases.
The clearance is the third in a growing family of machine-learning notification algorithms built to spot serious cardiac conditions from a routine 12-lead ECG, a test most patients already get.
The STABLED trial randomized 331 atrial fibrillation patients with a recent stroke to ablation plus anticoagulation or anticoagulation alone. The two groups ended up nearly identical.
Among watch wearers told their pulse looked irregular, a third had atrial fibrillation confirmed on a follow-up ECG patch. Most who were notified did not.
An individual-patient meta-analysis of 17,801 patients found a hazard ratio of 0.97 for death, reinfarction or heart failure — a result precise enough to make the question look settled.
EchoNext scored 77.3% accuracy on a 150-ECG set where 13 cardiologists averaged 64.0%. Its authors released the model weights and a 100,000-ECG labelled dataset alongside the paper.